From MRK’s 10-K on the pipeline pruning: Merck has discontinued internal development of MK-2866 (which is a SARM) under this agreement, and is currently discussing next steps with GTx.Page 128, 2nd paragraph http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzcxMDk4fENoaWxkSUQ9MzY4MDQ2fFR5cGU9MQ==&t=1